BioSpace News Archive

Flagship software platform further unifies pathology workflows and data across the R&D value chain

Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) announced today that it has closed a one-year extension of Company’s US$6.0 million secured

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction and pancreatic adenocarcinomas.

Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2023.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the Phase 1 study evaluating [225Ac]-FPI-2059 (FPI-2059).

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today its strategic, operational and financial results for the quarter and full year ended December 31, 2022.

New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics’ investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced that its partner, Athenex Pharmaceutical Division, has just started to commercialize its abbreviated new drug application approval from the U.S. Food and Drug Administration for its Generic Version of Magnesium Sulfate in Water for Injection, 2 g/50 mL, 4 g/100 mL and 4 g/50 mL, in Non-PVC, Single-Patient Use Containers.

Rentschler Biopharma SE is proud to announce that the company has been awarded CDMO Leadership Awards in the categories of Service, Reliability, Capabilities and Compatibility.